Top 5 Stocks to Buy Now
→ Read this warning immediately (From Porter & Company) (Ad)tc pixel Free MBX Stock Alerts

MBX Biosciences (MBX) Competitors

MBX Biosciences logo
$46.39 +2.48 (+5.65%)
Closing price 04:00 PM Eastern
Extended Trading
$45.51 -0.88 (-1.90%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MBX vs. LEGN, PTCT, MIRM, RYTM, and CNTA

Should you buy MBX Biosciences stock or one of its competitors? MarketBeat compares MBX Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MBX Biosciences include Legend Biotech (LEGN), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), Rhythm Pharmaceuticals (RYTM), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does MBX Biosciences compare to Legend Biotech?

MBX Biosciences (NASDAQ:MBX) and Legend Biotech (NASDAQ:LEGN) are both mid-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

MBX Biosciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$2.21N/A
Legend Biotech$1.14B4.78-$296.80M-$0.68N/A

MBX Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. MBX Biosciences' return on equity of -24.52% beat Legend Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -24.52% -23.59%
Legend Biotech -21.98%-24.92%-14.87%

MBX Biosciences presently has a consensus price target of $60.22, indicating a potential upside of 29.82%. Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 105.57%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than MBX Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77
Legend Biotech
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Legend Biotech had 5 more articles in the media than MBX Biosciences. MarketBeat recorded 6 mentions for Legend Biotech and 1 mentions for MBX Biosciences. Legend Biotech's average media sentiment score of 0.18 beat MBX Biosciences' score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Legend Biotech
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Legend Biotech beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to PTC Therapeutics?

MBX Biosciences (NASDAQ:MBX) and PTC Therapeutics (NASDAQ:PTCT) are both mid-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

MBX Biosciences presently has a consensus target price of $60.22, suggesting a potential upside of 29.82%. PTC Therapeutics has a consensus target price of $91.36, suggesting a potential upside of 11.23%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe MBX Biosciences is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77
PTC Therapeutics
2 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.71

MBX Biosciences has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than MBX Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MBX BiosciencesN/AN/A-$86.97M-$2.21N/A
PTC Therapeutics$1.73B3.94$682.64M-$2.33N/A

In the previous week, PTC Therapeutics had 12 more articles in the media than MBX Biosciences. MarketBeat recorded 13 mentions for PTC Therapeutics and 1 mentions for MBX Biosciences. PTC Therapeutics' average media sentiment score of 0.49 beat MBX Biosciences' score of 0.00 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MBX Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
PTC Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -22.58%. MBX Biosciences' return on equity of -24.52% beat PTC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MBX BiosciencesN/A -24.52% -23.59%
PTC Therapeutics -22.58%-362.45%-6.76%

Summary

MBX Biosciences beats PTC Therapeutics on 7 of the 12 factors compared between the two stocks.

How does MBX Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and MBX Biosciences (NASDAQ:MBX) are both mid-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Mirum Pharmaceuticals has a beta of 0.5, indicating that its share price is 50% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 7 more articles in the media than MBX Biosciences. MarketBeat recorded 8 mentions for Mirum Pharmaceuticals and 1 mentions for MBX Biosciences. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat MBX Biosciences' score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Mirum Pharmaceuticals currently has a consensus price target of $139.80, indicating a potential upside of 25.73%. MBX Biosciences has a consensus price target of $60.22, indicating a potential upside of 29.82%. Given MBX Biosciences' higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77

MBX Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat MBX Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-140.24% -11.28% -3.84%
MBX Biosciences N/A -24.52%-23.59%

Mirum Pharmaceuticals has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$521.31M13.01-$23.36M-$13.61N/A
MBX BiosciencesN/AN/A-$86.97M-$2.21N/A

Summary

Mirum Pharmaceuticals beats MBX Biosciences on 9 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and MBX Biosciences (NASDAQ:MBX) are both mid-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for Rhythm Pharmaceuticals and 1 mentions for MBX Biosciences. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat MBX Biosciences' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -93.33%. MBX Biosciences' return on equity of -24.52% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-93.33% -203.25% -44.99%
MBX Biosciences N/A -24.52%-23.59%

MBX Biosciences has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M38.35-$196.54M-$3.13N/A
MBX BiosciencesN/AN/A-$86.97M-$2.21N/A

Rhythm Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $133.13, indicating a potential upside of 25.36%. MBX Biosciences has a consensus target price of $60.22, indicating a potential upside of 29.82%. Given MBX Biosciences' higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.83
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77

Summary

MBX Biosciences beats Rhythm Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and MBX Biosciences (NASDAQ:MBX) are both mid-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

In the previous week, Centessa Pharmaceuticals had 2 more articles in the media than MBX Biosciences. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 1 mentions for MBX Biosciences. Centessa Pharmaceuticals' average media sentiment score of 0.72 beat MBX Biosciences' score of 0.00 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Centessa Pharmaceuticals
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MBX Biosciences' return on equity of -24.52% beat Centessa Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Centessa PharmaceuticalsN/A -60.37% -44.17%
MBX Biosciences N/A -24.52%-23.59%

Centessa Pharmaceuticals currently has a consensus price target of $41.33, suggesting a potential upside of 2.06%. MBX Biosciences has a consensus price target of $60.22, suggesting a potential upside of 29.82%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Centessa Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Centessa Pharmaceuticals
1 Sell rating(s)
9 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.21
MBX Biosciences
2 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.77

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.75, suggesting that its stock price is 25% less volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Centessa Pharmaceuticals$15M417.77-$197.53M-$1.79N/A
MBX BiosciencesN/AN/A-$86.97M-$2.21N/A

Summary

MBX Biosciences beats Centessa Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

Export
MetricMBX BiosciencesPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$2.09B$930.38M$4.35B$12.39B
Dividend YieldN/A4.84%10.93%5.83%
P/E Ratio-20.991.4222.0023.98
Price / SalesN/A119.68162.46109.04
Price / CashN/A20.0640.7754.51
Price / Book5.647.7518.626.50
Net Income-$86.97M-$3.91M$115.37M$336.88M
7 Day Performance15.71%1.41%-0.49%-0.22%
1 Month Performance45.65%2.02%-1.84%0.77%
1 Year PerformanceN/A50.51%12.71%31.57%

MBX Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
MBX Biosciences
2.0663 of 5 stars		$46.39
+5.6%		$60.22
+29.8%		N/A$2.09BN/AN/AN/A
LEGN
Legend Biotech
4.4006 of 5 stars		$35.87
-1.1%		$60.23
+67.9%		-13.7%$6.66B$1.03BN/A2,965
PTCT
PTC Therapeutics
2.508 of 5 stars		$75.14
+0.6%		$91.36
+21.6%		+61.3%$6.23B$1.73BN/A1,410
MIRM
Mirum Pharmaceuticals
4.1272 of 5 stars		$99.35
-0.2%		$138.36
+39.3%		+114.1%$6.06B$569.61MN/A140
RYTM
Rhythm Pharmaceuticals
2.896 of 5 stars		$88.38
+0.8%		$131.81
+49.1%		+63.6%$6.06B$217.17MN/A140

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 6/23/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel